

Managing the Hepatitis C Virus: Challenges and Opportunities for Managed Care

Instructions

After reading “Managing the Hepatitis C Virus: Challenges and Opportunities for Managed Care,” complete the program evaluation and select the 1 best answer to each of the posttest questions.

A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the University of Cincinnati. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Cincinnati designates this enduring material activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement



Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.5 contact hours (0.25 CEUs) under the ACPE universal program number of 0290-9999-11-016-H01-P. This program is available for CE credit through March 28, 2012.

Posttest Questions

1. Hepatitis C infection is the leading cause of _____ in the United States.
 - a. Intravenous drug use
 - b. Liver transplantation
 - c. Liver fibrosis
 - d. Liver-related mortality

2. What percentage of individuals acutely infected with HCV will progress to chronic infection?
 - a. 40% to 50%
 - b. 55% to 60%
 - c. 75% to 80%
 - d. 90%

3. **Even after individuals with HCV infection clear the virus, they can be reinfected.**
 - a. True
 - b. False

4. **The leading source of HCV infection is:**
 - a. Blood transfusions
 - b. Male-to-male sexual contact
 - c. Blood transfusions
 - d. Intravenous drug use

5. **The gold standard in the treatment of chronic HCV infection is:**
 - a. Interferon alfa-2a or alfa-2b
 - b. Pegylated interferon alfa-2a or alfa-2b
 - c. Interferon alfa-2a or alfa-2b with ribavirin
 - d. Pegylated interferon alfa-2a or alfa-2b with ribavirin

6. **Patients with genotype 2 or 3 HCV infection typically require treatment for at least 48 weeks.**
 - a. True
 - b. False

7. **The absence of HCV RNA in serum determined by a sensitive PCR assay 24 weeks after therapy discontinuation defines an:**
 - a. EVR
 - b. RVR
 - c. ETR
 - d. SVR

8. **The “age wave” of HCV infection refers to:**
 - a. The difficulty of treating HCV in an elderly population
 - b. The growing incidence of hepatocellular cancer
 - c. The aging of a population infected in their 20s and 30s and the resulting complications
 - d. The growing incidence of new infections in those 50 years and older

9. **What percentage of individuals in the United States infected with HCV are baby boomers?**
 - a. 35%
 - b. 46%
 - c. 52%
 - d. 66%

10. **What percentage of those with chronic HCV infection is expected to experience cirrhosis by 2030?**
 - a. 16%
 - b. 25%
 - c. 45%
 - d. 66%

11. **Treating HCV infection in patients coinfecting with HIV is cost-effective.**
 - a. True
 - b. False

12. **Which of the following may limit HCV infection therapy in an elderly population?**
 - a. Hypertension
 - b. Chronic obstructive lung disease
 - c. Diabetes
 - d. All of the above

13. **Medical costs for patients with genotype 2 or 3 HCV infection are higher than those with genotype 1 because:**
 - a. More individuals with genotype 2 or 3 receive treatment
 - b. Treatment is more effective in those with genotypes 2 and 3
 - c. Patients with genotypes 2 and 3 require longer duration of treatment
 - d. None of the above

14. **Nonpegylated interferon/ribavirin is more cost-effective than pegylated interferon/ribavirin because the medication costs less.**
 - a. True
 - b. False

15. Approximately what percentage of patients with HCV genotype 1 infection achieve an SVR with the current standard of care?
- 20%
 - 40%
 - 60%
 - 80%
16. Which of the following is not associated with patient response to HCV infection therapy?
- IL-28B genotype
 - Sex
 - Height
 - Ethnicity
17. In the RESPOND trials, the most common adverse event associated with boceprevir was:
- Anemia
 - Neutropenia
 - Urinary tract infections
 - Bradycardia
18. Which of the following is a common adverse event associated with telaprevir?
- Headache
 - Rash
 - Dysguesia
 - Nausea
19. In a phase 2 trial with vaniprevir, RVR rates with the study drug were approximately _____ among the dosing regimens:
- 45% to 59%
 - 60% to 67%
 - 69% to 82%
 - 85% to 90%
20. Which of the following is not a promising nucleoside inhibitor in development?
- PSI-7977
 - RG7128
 - PSI-938
 - NM283

Physician Credits

(PLEASE PRINT CLEARLY)

Name/Degree _____

Street _____

City _____

State/Zip _____

Daytime Phone _____

Fax _____

E-mail _____

Date of Birth _____

Release Date: **March 28, 2011**

Expiration Date: **March 28, 2012**

CME Test Form

Managing the Hepatitis C Virus: Challenges and Opportunities for Managed Care

1.	a	b	c	d
2.	a	b	c	d
3.	a	b		
4.	a	b	c	d
5.	a	b	c	d
6.	a	b		
7.	a	b	c	d
8.	a	b	c	d
9.	a	b	c	d
10.	a	b	c	d
11.	a	b		
12.	a	b	c	d
13.	a	b	c	d
14.	a	b		
15.	a	b	c	d
16.	a	b	c	d
17.	a	b	c	d
18.	a	b	c	d
19.	a	b	c	d
20.	a	b	c	d

Answer Form Instructions: Testing and Grading Procedures

- Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CME credits earned. This form should be safeguarded and may be used as documentation of credits earned.
- Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no cost.
- All answers should be recorded on the answer form.
- To receive credit certification electronically, please provide your e-mail address. Detach and mail or fax the test portion of this page to:
University of Cincinnati, Office of CME, PO Box 670556, Cincinnati, OH 45267-0567; phone: 513-558-7277; fax: 513-558-1708.
Please print clearly to ensure receipt of CME credit.
- To receive credit and an immediate certificate, register at http://webcentral.uc.edu/cpd_online2/ and complete the test or reader survey. If you have previously registered, enter your user name and password to log in. Otherwise, click **New User? Register!** and complete the registration process (user ID and password will be e-mailed to you immediately). Once you log in, click **CME Text** and scroll down through the course listings to locate this supplement. A345

CME Activity Evaluation

How long did it take you to complete this activity?

_____ minutes

How well did this activity achieve its educational objectives?

Very well Well Somewhat Not at all

What overall grade would you assign this activity?

A B C D

Did this activity exhibit promotional bias for any pharmaceutical agents?

Yes No

Will you make changes in your practice as a result of information presented in this lesson?

Yes No

Pharmacy Credits

Instructions

Scoring Options

1. This lesson is FREE online; receive instant grading and download your certificate at **www.PharmacyTimes.com**
2. Mail and/or fax will be processed for a nominal fee of \$10 (see below for address and fax number).

Please mail completed forms to this address:

Pharmacy Times CE Department
666 Plainsboro Road, Suite 300
Plainsboro, NJ 08536

Testing and Grading Procedures

1. Each participant achieving a passing grade of 70% or higher on any examination will receive a statement of credit giving the number of CE credits earned. This form should be safeguarded and may be used as documentation of credits earned.
2. Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no extra cost.
3. All answers should be recorded on the answer form. For each question, decide which choice is the best answer, and circle the letter of the response representing your choice.
4. Go to www.PharmacyTimes.com to submit your responses at no fee; or mail completed exam form for a nominal fee of \$10 to:

Pharmacy Times CE Department
666 Plainsboro Road, Suite 300
Plainsboro, NJ 08536
or fax the form to: 609-257-0000

Please email all inquiries to: ceinfo@pharmacytimes.com or call us at 800-597-6372.

Evaluation form follows.

A345

Please print clearly.

CE Answer Form: MARCH 2011 • Managing the Hepatitis C Virus: Challenges and Opportunities for Managed Care			
PROGRAM 0290-9999-11-016-H01-P (TEST VALID THROUGH MARCH 28, 2012. NO CREDIT WILL BE GIVEN AFTER THIS DATE.)			
1. a b c d	6. a b c d	11. a b c d	16. a b c d
2. a b c d	7. a b c d	12. a b c d	17. a b c d
3. a b c d	8. a b c d	13. a b c d	18. a b c d
4. a b c d	9. a b c d	14. a b c d	19. a b c d
5. a b c d	10. a b c d	15. a b c d	20. a b c d
<input type="checkbox"/> Presently Enrolled in CE Program		<input type="checkbox"/> Nonsubscriber Participant Pharmacist	
Name:		E-mail:	
Address:			
City:		State:	Zip: Daytime Phone:
Specialty: <input type="checkbox"/> Pharmacist <input type="checkbox"/> Pharmacy Technician <input type="checkbox"/> Other (Specify)			

CE Evaluation Form: MARCH 2011 • Managing the Hepatitis C Virus: Challenges and Opportunities for Managed Care					
Please rate the effectiveness of this activity. Your input and comments are encouraged and appreciated.					
	Poor		Average		Excellent
1. Overall, how would you rate this activity?	1	2	3	4	5
2. Overall, how would you rate the work of the instructor(s)?	1	2	3	4	5
3. How would you rate the quality of the instructional materials?	1	2	3	4	5
4. Were the learning objectives of this activity met?	Not at all		Partially		Completely
(Objective 1)	1	2	3	4	5
(Objective 2)	1	2	3	4	5
(Objective 3)	1	2	3	4	5
(Objective 4)	1	2	3	4	5
(Objective 5)	1	2	3	4	5
5. Was the activity useful and relevant to your practice?	1	2	3	4	5
6. Do you believe the subject matter was presented objectively? Yes No If no, please explain: _____					
7. Do you intend to make any changes to your practice based on learnings from this program? a. Yes b. No If yes , which of the following changes do you intend to implement? (<i>Please select all that apply</i>) a. Provide more in-depth counseling to patients b. Proactively talk to patients with this disease/problem/issue c. Educate staff to better help patients d. Seek more resources to provide to patients e. Implement disease management program f. Improve monitoring for adherence/persistence g. Other _____ h. None		8. Do you anticipate any barriers in trying to implement changes in your practice? a. Yes b. No c. Don't know If yes , what barriers do you anticipate? (<i>Please select all that apply</i>) a. Lack of time b. Lack of resources c. Lack of pharmacy technician help d. Corporate focus is elsewhere e. Legal issues f. Insurance issues/restrictions g. Patients don't want this service or have no time h. Other _____ i. None		9. Based on the learning from this activity, overall how confident are you in your ability to counsel/educate/manage the disease/condition/problem (<i>1 being NOT confident and 5 being VERY confident</i>)? a. 1 (Not confident) b. 2 c. 3 (Somewhat confident) d. 4 e. 5 (Very confident)	
10. What other topics related to this topic would you like to explore in future CE activities? _____ _____ _____					

Please mail this form to: *Pharmacy Times* CE Department, 666 Plainsboro Road, Suite 300, Plainsboro, NJ 08536